AGL

agilon health, inc.
13 filings tracked
healthcarehealthcare servicesSMALL ($300M-2B)

Hegelian Dialectical Ticker Hub

Quarterly Detail

Chronological Filing Evolution (Hacer jugar/hacer clic para filtrar)

Tesis (Bull Case Evolution)

AGL Private Credit Income Fund has demonstrated significant scaling capabilities in the first quarter of 2026, with net investment income surging to $13.8 million. The fund has successfully deployed over $1.2 billion into a diversified portfolio of floating-rate senior secured loans, achieving a weighted average contractual interest rate of 8.6%. This growth is supported by a disciplined approach to leverage and a strategic partnership with Barclays to ensure premium deal flow. Operational efficiency is improving as the fund optimizes its cost structure. The net expense ratio after advisory support fell to 12.9% from 14.3% in the prior year. Furthermore, the fund's strategic move to transfer $230 million in loans to a joint venture with Goldman Sachs' Vintage Strategies allowed AGL to reduce debt while retaining a 25% economic interest, showcasing a sophisticated approach to capital recycling and balance sheet management.

Perspectiva Alcista

Antítesis (Bear Case / Riesgos Estructurales)

Despite top-line growth, AGL faces intensifying pressure on its margins. Interest and financing expenses jumped 95% year-over-year to $13 million, while net expenses rose 111%. This trend has left the fund with a razor-thin margin of safety, as net investment income of $0.61 per share barely covers the $0.60 per share distribution. The fund's reliance on the Adviser's expense-support waiver further suggests that the underlying operational costs remain high. Asset quality and valuation risks are also prominent, with 96% of debt investments classified as Level 3, meaning they rely on unobservable inputs. A slight decline in NAV per share from $23.40 to $23.33, coupled with a $1.9 million increase in unrealized depreciation, signals potential erosion in portfolio value. With net leverage climbing to 5.7x, the fund is increasingly sensitive to credit defaults and market volatility.

Factores de Riesgo

Síntesis (Veredicto y Resolución)

The Q1 2026 filing reveals a fund in a high-growth transition phase, balancing aggressive asset accumulation with the rising costs of leverage. While the surge in net investment income and the successful launch of the AGL EPCI I joint venture point toward a scalable and institutional-grade platform, the narrowing gap between earnings and distributions is a critical point of fragility. Investors are essentially betting on the fund's ability to maintain its 10.4% yield without eroding NAV. The transition to a perpetual-life BDC structure and the planned 2028 share repurchase program provide a long-term framework for value creation, but the immediate focus remains on the stability of the floating-rate portfolio in a shifting interest rate environment.

Trimestre Seleccionado

Core Takeaway (Punto de Giro)

The fund is successfully scaling its private credit book and optimizing its balance sheet, but rising interest expenses are squeezing the margin between NII and payouts.

Investor Lens (Foco de Inversión)

The trade-off is between the attractive 10%+ yield and the risk of NAV erosion if NII fails to cover distributions.

Watch Next (Próximos Hitos)

The 2028 share repurchase program commencement and quarterly NII vs. distribution coverage.

Gráfico de Momentum de Sentimiento (Dialectical Chart)

Ratio neto trimestral de Tesis y Antítesis (Hacer clic en los nodos para seleccionar trimestre)

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.42Q2 '26 (10-Q)+0.27Q2 '26 (10-Q)

Signal Timeline

21 de 45
Filtros Activos:Trimestre: Q2 '26 (10-Q)
bullishMay 8

Net investment income surged 157% year-over-year to $13.8 million.

earnings beat
90%
bearishMay 8

Interest and financing expenses jumped 95% to $13 million, squeezing net margins.

margin compression
70%
bullishMay 8

Transferred $230 million in loans to a joint venture to reduce outstanding borrowings.

debt restructure
60%
bullishMay 8

Net investment income surged 157% year-over-year to $13.8 million.

earnings beat
90%
bearishMay 8

Interest and financing expenses jumped 95% to $13 million, squeezing net margins.

margin compression
70%
bullishMay 8

Transferred $230 million in loans to a joint venture to reduce outstanding borrowings.

debt restructure
60%
bullishMay 8

Net investment income surged 157% year-over-year to $13.8 million.

earnings beat
90%
bearishMay 8

Interest and financing expenses jumped 95% to $13 million, squeezing net margins.

margin compression
70%
bullishMay 8

Transferred $230 million in loans to a joint venture to reduce outstanding borrowings.

debt restructure
60%
bullishMay 8

Net investment income surged 157% year-over-year to $13.8 million.

earnings beat
90%
bearishMay 8

Interest and financing expenses jumped 95% to $13 million, squeezing net margins.

margin compression
70%
bullishMay 8

Transferred $230 million in loans to a joint venture to reduce outstanding borrowings.

debt restructure
60%
bullishMay 8

Net investment income surged 157% year-over-year to $13.8 million.

earnings beat
90%
bearishMay 8

Interest and financing expenses jumped 95% to $13 million, squeezing net margins.

margin compression
70%
bullishMay 8

Transferred $230 million in loans to a joint venture to reduce outstanding borrowings.

debt restructure
60%
bullishMay 8

Net investment income surged 157% year-over-year to $13.8 million.

earnings beat
90%
bearishMay 8

Interest and financing expenses jumped 95% to $13 million, squeezing net margins.

margin compression
70%
bullishMay 8

Transferred $230 million in loans to a joint venture to reduce outstanding borrowings.

debt restructure
60%
bullishMay 8

Net investment income surged 157% year-over-year to $13.8 million.

earnings beat
90%
bearishMay 8

Interest and financing expenses jumped 95% to $13 million, squeezing net margins.

margin compression
70%
bullishMay 8

Transferred $230 million in loans to a joint venture to reduce outstanding borrowings.

debt restructure
60%

Filing History

10-QMay 8, 2026

The Q1 2026 filing reveals a fund in a high-growth transition phase, balancing aggressive asset accumulation with the rising costs of leverage. While the surge in net investment income and the successful launch of the AGL EPCI I joint venture point toward a scalable and institutional-grade platform, the narrowing gap between earnings and distributions is a critical point of fragility. Investors are essentially betting on the fund's ability to maintain its 10.4% yield without eroding NAV. The transition to a perpetual-life BDC structure and the planned 2028 share repurchase program provide a long-term framework for value creation, but the immediate focus remains on the stability of the floating-rate portfolio in a shifting interest rate environment.

10-QMay 6, 2026

The Q1 2026 filing presents a stark dichotomy: a company that has successfully engineered a short-term profit surge by cutting its losses, versus a business whose long-term viability is questioned by a shrinking member base. Agilon has clearly improved its immediate cash flow and net income, proving that its platform can be profitable when focused on a smaller, higher-quality footprint. The successful execution of a reverse stock split to regain NYSE compliance provides a temporary reprieve from delisting risks. However, the long-term investment case hinges on whether Agilon can return to growth without sacrificing these new margins. The tension between the bull case of 'operational triage' and the bear case of 'market share erosion' will be decided by the company's ability to attract new members under the new leadership of Tim O'Rourke while managing a precarious debt structure and significant legal headwinds. For now, the company has bought itself time, but the underlying risk of payor concentration remains a critical vulnerability.